Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research350

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research350

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional350
Observational33
Expanded access10
Not on ClinicalTrials.gov815

Phase

Not applicable126
Phase 389
Phase 260
Phase 124
Phase 1/224
Phase 414

Investigator

Gail J Roboz8
Ashish Saxena7
Harini Sarva7
Manish A Shah7
Alexander Ja-Ho Chou6

Department

Medicine184
Pediatrics39
Psychiatry26
Surgery17
Neurology14

Show all 20Show fewer

Condition

Breast Neoplasms14
Crohn Disease12
Leukemia, Myeloid, Acute11
Obesity10
Prostatic Neoplasms10

Intervention type

Drug193
Device58
Other53
Procedure52
Biological43
Behavioral38

Sponsor type

Industry162
WCM (investigator-initiated)96
Other academic65
NIH18
Cooperative group9

Start date

Has results posted2

Recruiting×Interventional×Clear all

Showing 1–20 of 350 studiesSort:

RecruitingInterventional · Phase 1NCT02074839 ↗
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional350
Observational33
Expanded access10
Not on ClinicalTrials.gov815

Phase

Not applicable126
Phase 389
Phase 260
Phase 124
Phase 1/224
Phase 414

Investigator

Gail J Roboz8
Ashish Saxena7
Harini Sarva7
Manish A Shah7
Alexander Ja-Ho Chou6

Department

Medicine184
Pediatrics39
Psychiatry26
Surgery17
Neurology14

Show all 20Show fewer

Condition

Breast Neoplasms14
Crohn Disease12
Leukemia, Myeloid, Acute11
Obesity10
Prostatic Neoplasms10

Intervention type

Drug193
Device58
Other53
Procedure52
Biological43
Behavioral38

Sponsor type

Industry162
WCM (investigator-initiated)96
Other academic65
NIH18
Cooperative group9

Start date

Has results posted2

Recruiting×Interventional×Clear all

Showing 1–20 of 350 studiesSort:

RecruitingInterventional · Phase 1NCT02074839 ↗
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase 2/312

Early phase 11

Show all 50

Show fewer

Silvia Chiara Formenti6
Parag Goyal6
Aliza B Solomon5
Ellen J Scherl5
Jia Ruan5
Mario Fl Gaudino5
Sujit Sheth5
Sonal Kumar5
Brian DeRubertis4
Conor Liston4
Jim W. Cheung4
Massimo Cristofanilli4
Mateo Mejia Saldarriaga4
Pinkal Desai4
Samuel Kim4
Scott T. Tagawa4
Abhishek Jaywant3
Anna C Pavlick3
Anna Podolanczuk3
Cora Sternberg3
David M. Otterburn3
Daniel W Skupski3
Erin Mulvey3
Erica Phillips3
Jaikirshan Khatri3
JoAnn Difede3
Jaclyn Rosenzweig3
James E. Ip3
Madeline R. Sterling3
Maria Teresa DeSancho3
Joan Stilling3
Randy Longman3
Rohit Kumar Jain3
Reem Z. Sharaiha3
Shmuel Chen3
Ana C. Krieger2
Anthony O. Ahmed2
Alpana P. Shukla2
Bernhard Kuhn2
Catherine McGuinn2
Catherine Butkus Small2
Cheguevara Afaneh2
Christine M Salvatore2
Caitlin K Gribbin2
Dikoma C. Shungu2

Obstetrics and Gynecology12
Radiation Oncology10
Cardiothoracic Surgery9
Radiology9
Neurological Surgery6
Population Health Sciences4
Rehabilitation Medicine4
Orthopaedic Surgery3
Urology3
Anesthesiology2
Dermatology2
Emergency Medicine2
Genetic Medicine2
Otolaryngology Head and Neck Surgery1
Pharmacology1

Show all 50

Show fewer

Depression9
Heart Failure9
Hematologic Neoplasms9
Neoplasms9
Atrial Fibrillation7
Burkitt Lymphoma7
Carcinoma, Non-Small-Cell Lung7
Colitis, Ulcerative7
Lymphoma, Non-Hodgkin7
Multiple Myeloma7
Overweight7
Recurrence7
Colorectal Neoplasms6
Leukemia6
Pain6
Parkinson Disease6
Adenocarcinoma Of Esophagus5
Anxiety Disorders5
Cardiovascular Diseases5
Cognitive Dysfunction5
Coronary Artery Disease5
Depressive Disorder, Major5
Fibrosis5
Inflammatory Bowel Diseases5
Lung Neoplasms5
Stroke5
Ischemic Stroke4
Leukemia, Lymphocytic, Chronic, B-Cell4
Lymphoma4
Lymphoma, Mantle-Cell4
Melanoma4
Myelodysplastic Syndromes4
Neoplasm Metastasis4
Agnosia3
Alzheimer Disease3
Cardiomyopathies3
Cerebral Hemorrhage3
Chronic Limb-Threatening Ischemia3
Dementia3
Depressive Disorder, Treatment-Resistant3
Diabetes Mellitus3
Diabetes Mellitus, Type 23
Hemorrhage3
Leukemia, Biphenotypic, Acute3
Lymphoma, B-Cell, Marginal Zone3

Intervention: Drug: AG-120
Dates: Mar 2014 – Dec 2026 (est.)
Sponsor: Agios Pharmaceuticals, Inc.

Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more

RecruitingInterventional · Not applicableNCT02235857 ↗

Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System

Darshana M DadhaniaPI

Intervention: Device: LIPOSORBER® LA-15 System
Dates: May 2015 – Sep 2027 (est.)
Sponsor: Kaneka Pharma America Corporation

Focal Segmental Glomerulosclerosis

RecruitingInterventional · Phase 2NCT02523014 ↗

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Rajiv S. MaggePI

Intervention: Drug: Vismodegib · Drug: FAK Inhibitor GSK2256098 · Drug: Capivasertib · Drug: Abemaciclib
Dates: Sep 2015 – Jun 2028 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation

RecruitingInterventional · Phase 3NCT02582697 ↗

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Alexander Ja-Ho ChouPI

Intervention: Drug: Bleomycin (active name: Bleomycin Sulfate) · Drug: Etoposide · Drug: Cisplatin · Drug: Pegylated G-CSF (Pegfilgrastim) · Drug: Filgrastim
Dates: Feb 2014 – Dec 2029 (est.)
Sponsor: Children's Oncology Group

Germ Cell Tumor

RecruitingInterventional · Phase 2NCT02974647 ↗

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Jia RuanPI

Intervention: Drug: Ruxolitinib
Dates: Nov 2016 – Nov 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Lymphoma

RecruitingInterventional · Phase 2/3NCT03435796 ↗

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Roger N PearsePI

Intervention: Genetic: Gene-modified (GM) T cell therapy
Dates: Jul 2018 – May 2043 (est.)
Sponsor: Celgene Corporation

Neoplasms

RecruitingInterventional · Phase 1/2NCT03449238 ↗

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Silvia Chiara FormentiPI

Intervention: Drug: Pembrolizumab
Dates: Nov 2018 – Dec 2028 (est.)
Sponsor: Weill Medical College of Cornell University

Metastatic Breast CancerBrain Metastases

RecruitingInterventional · Phase 1/2NCT03556228 ↗

A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

Ashish SaxenaPI

Intervention: Drug: VMD-928 100 mg Tablet · Drug: VMD-928 Tablet and Pembrolizumab (200 mg)
Dates: Jun 2018 – Dec 2027 (est.)
Sponsor: VM Oncology, llc

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more

RecruitingInterventional · Phase 2NCT03606967 ↗

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Massimo CristofanilliPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Durvalumab · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Nab-paclitaxel · Biological: Personalized Synthetic Long Peptide Vaccine · Drug: Poly ICLC · Biological: Sacituzumab Govitecan · Biological: Tremelimumab
Dates: Apr 2021 – Dec 2026 (est.)
Sponsor: National Cancer Institute

Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma

RecruitingInterventional · Phase 1NCT03666000 ↗

A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sebastian A. MayerPI

Intervention: Biological: Azer-cel · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: IL-2 · Drug: Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
Dates: Mar 2019 – Jun 2027 (est.)
Sponsor: Precision BioSciences, Inc.

Non-Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia+1 more

RecruitingInterventional · Not applicableNCT03671889 ↗

Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease

Michael G KaplittPI

Intervention: Device: Blood Brain Barrier (BBB) Disruption
Dates: Sep 2018 – Jan 2028 (est.)
Sponsor: InSightec

Alzheimer Disease

RecruitingInterventional · Phase 3NCT03678025 ↗

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Douglas S ScherrPI

Intervention: Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin
Dates: Sep 2018 – Apr 2033 (est.)
Sponsor: Southwest Oncology Group

Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

RecruitingInterventional · Phase 2NCT03739814 ↗

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Ellen K. RitchiePI

Intervention: Procedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Biological: Inotuzumab Ozogamicin · Procedure: Lumbar Puncture · Drug: Ponatinib
Dates: May 2019 – Feb 2027 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

RecruitingInterventional · Phase 2NCT03804944 ↗

Converting HR+ Breast Cancer Into an Individualized Vaccine

Silvia Chiara FormentiPI

Intervention: Radiation: Focal Radiation therapy · Drug: Pembrolizumab (200mg IV for 30 minutes · Biological: CDX-301
Dates: Mar 2020 – Dec 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer

RecruitingInterventional · Phase 3NCT03808922 ↗

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

Rosy Priya L KodiyanplakkalPI

Intervention: Drug: DAS181 · Drug: Placebo · Drug: DAS181 COVID-19 · Drug: DAS181 OL
Dates: May 2019 – Sep 2028 (est.)
Sponsor: Ansun BioPharma, Inc.

Lower Respiratory Tract InfectionParainfluenzaImmunocompromised+1 more

RecruitingInterventional · Phase 1NCT03816345 ↗

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Ashish SaxenaPI

Intervention: Procedure: Biospecimen Collection · Drug: Cabozantinib · Drug: Fluoropyrimidine · Biological: Ipilimumab · Biological: Nivolumab · Drug: Platinum Compound · Drug: Platinum Doublet
Dates: Jul 2019 – Mar 2028 (est.)
Sponsor: National Cancer Institute

Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more

RecruitingInterventional · Phase 2NCT03866382 ↗

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Cora SternbergPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Echocardiography Test · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography
Dates: May 2019 – Feb 2027 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more

RecruitingInterventional · Phase 2NCT03899155 ↗

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Ana M. MolinaPI

Intervention: Drug: Nivolumab · Drug: Ipilimumab · Drug: Cabozantinib · Drug: Trametinib · Drug: Relatlimab · Drug: Nivolumab + Relatlimab · Drug: Capecitabine · Drug: Bevacizumab · Drug: Temozolomide · Drug: Rucaparib · Drug: Daratumumab · Drug: Regorafinib · Drug: Leucovorin · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Enzalutamide · Drug: Sunitinib · Drug: Pemetrexed · Drug: Pembrolizumab
Dates: Aug 2019 – Aug 2029 (est.)
Sponsor: Bristol-Myers Squibb Company

Cancer

RecruitingInterventional · Phase 3NCT03907046 ↗

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery

Maryna SkliutPIHooman KamelPI

Intervention: Drug: Apixaban · Drug: Aspirin
Dates: Jan 2020 – Apr 2027 (est.)
Sponsor: Yale University

Intracerebral HemorrhageAtrial Fibrillation

RecruitingInterventional · Phase 3NCT03936361 ↗

STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS

Santosh Bhaskar MurthyPI

Intervention: Drug: Statins
Dates: Jun 2020 – Dec 2028 (est.)
Sponsor: Beth Israel Deaconess Medical Center, Inc.

Intracerebral Hemorrhage

‹ Prev1 2 3 4 5…14 15 16 17 18 Next ›